Uh, no real evidence of that.
1). Other companies are actually behind Leronlimab in terms of timeframes.
2). None are targeting the broad first line cause of the cytokine storm, and are limited in their scope of what inflammatory markers they target.
3). I personally don’t believe a ‘buyout’ is imminent. I believe that Nader misunderstood the question when asked today. Someone asked about buyout, and I think Nader was thinking ‘partnership’, although someone can correct me if I’m wrong. Otherwise, why even bother with Up-listing language?
4). Vaccines are a LONG way off compared to data results from Leronlimab.
All my opinion.